GlassScriptPhysician profile
Daniel Tres Campbell
NPI 1396268058
$2,699.42
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,684 · 2022: $15.55.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $584.89 | 2021 | |
| Novo Nordisk INC | $511.87 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $266.31 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.17 | 2021 | |
| Astellas Pharma US INC | $177.27 | 2021 | |
| Lilly USA, LLC | $158.06 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $151.99 | 2021 | |
| Amgen INC. | $142.68 | 2021 | |
| Glaxosmithkline, LLC. | $82.05 | 2021 | |
| Merck Sharp & Dohme LLC | $47.86 | 2021 | |
| Jazz Pharmaceuticals INC. | $39.07 | 2021 | |
| Sanofi-Aventis U.S. LLC | $38.14 | 2021 | |
| Biogen, INC. | $34.39 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.02 | 2021 | |
| Novartis Pharmaceuticals Corporation | $29.63 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $23.75 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.58 | 2021 | |
| Paratek Pharmaceuticals, INC. | $22.44 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $20.00 | 2021 | |
| Daiichi Sankyo INC. | $19.87 | 2021 | |
| Ibsa Pharma INC. | $18.02 | 2021 | |
| Pfizer INC. | $17.62 | 2021 | |
| Ethicon US, LLC | $16.14 | 2021 | |
| Pacira Therapeutics, INC. | $16.07 | 2021 | |
| Clarus Therapeutics INC. | $13.21 | 2021 | |
| Avion Pharmaceuticals | $11.82 | 2021 | |
| Vistapharm, INC. | $11.50 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.